This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Freedman, J. E. Search for Related Content PubMed PubMed Citation Articles by Freedman, J. E. Related Collections Aggregation Platelet function inhibitors Platelets

(Circulation. 2006;113:2865-2867.)
© 2006 American Heart Association, Inc.

Editorial

The Aspirin Resistance Controversy

Clinical Entity or Platelet Heterogeneity?

Jane E. Freedman, MD

From the Division of Cardiology, Boston University School of Medicine, Boston, Mass.

Correspondence to Jane E. Freedman, MD, Boston University School of Medicine, 715 Albany St, W507, Boston, MA 02118. E-mail freedmaj@bu.edu

Key Words: Editorials • aspirin • platelets • thrombosis • thromboxane

An extract of the first 250 words of the full text is provided, because this article has no abstract.

In acute coronary syndromes, rupture or fissuring of the atherosclerotic plaque exposes the subendothelium and lipid core, which leads to platelet adhesion and activation. Although the most commonly used inhibitor of this process is aspirin, information about its limitations has grown over the past decade. Because the absolute risk of recurrent vascular events among patients treated with aspirin remains relatively high (8% to 18% after 2 years),¹ a concept known as "aspirin resistance" has flourished. Aspirin resistance has been defined both as a clinical entity (thrombotic event while taking aspirin) and by a myriad of altered biomarkers and enhanced platelet function testing. Although many embrace this concept, others believe that aspirin resistance may reflect treatment failure rather than "resistance" to aspirin.²

Article p 2888

Aspirin-related compounds are among the oldest known medicinal substances, with stone tablets documenting the use of willow leaf (a source of salicylic acid) dating back to the Sumerian period.³ Controversy surrounding the use of aspirin can be traced back to the Greek empire, when Hippocrates was a proponent of willow bark for pain, whereas Dioscorides preferred coriander.⁴ We will never know whether Dioscorides was merely resistant to the beneficial properties of aspirin because thousands of years later we are still trying to understand and define the individual variability seen with its use.

The antithrombotic properties of aspirin were first reported in the Mississippi Valley Medical Journal in 1953, and, in the half century since, the benefits of aspirin’s platelet inhibitory properties have been documented in thousands . . . [Full Text of this Article]

This article has been cited by other articles:

				J. E. Herrera-Galeano, D. M. Becker, A. F. Wilson, L. R. Yanek, P. Bray, D. Vaidya, N. Faraday, and L. C. Becker A Novel Variant in the Platelet Endothelial Aggregation Receptor-1 Gene Is Associated With Increased Platelet Aggregability Arterioscler Thromb Vasc Biol, August 1, 2008; 28(8): 1484 - 1490. [Abstract] [Full Text] [PDF]

				J. Rehman An Inconvenient Truth: Recognizing Individual Differences in Arteriogenesis Circ. Res., May 23, 2008; 102(10): 1146 - 1147. [Full Text] [PDF]

				J. E. Freedman Heritability, Platelet Function, and Aspirin: A Link Established but Cause Unknown Circulation, May 15, 2007; 115(19): 2468 - 2470. [Full Text] [PDF]